ADVERTISEMENT

Zydus Lifesciences Arm Gets U.S. FDA Nod For Drug To Treat Depression

The drug will be manufactured at the group's formulation manufacturing facility at Moraiya in Ahmedabad, it added.

<div class="paragraphs"><p>(Photo by <a href="https://unsplash.com/@soumeya?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">The-Lore</a> on <a href="https://unsplash.com/photos/rRBtKW_aw_U?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Unsplash</a>)</p></div>
(Photo by The-Lore on Unsplash)

Zydus Lifesciences Ltd. on Monday said its U.S. unit has received tentative approval from the U.S. Food and Drug Administration to market generic Levomilnacipran extended-release capsules used to treat depression.

Zydus Pharmaceuticals (USA) Inc. received a tentative approval from the U.S. drug regulator to market Levomilnacipran extended-release capsules of strengths 20 mg, 40 mg, 80 mg, and 120 mg, Zydus Lifesciences said in a regulatory filing.

The drug will be manufactured at the group's formulation manufacturing facility at Moraiya in Ahmedabad, it added.

Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor indicated for the treatment of major depressive disorder in adults, the drug maker said.

The capsules had annual sales of $85 million (Rs 694.22 crore) in the U.S., the company said citing IQVIA MAT September 2022 data.